Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Common Equity (2016 - 2025)

Capricor Therapeutics has reported Common Equity over the past 15 years, most recently at $305.8 million for Q4 2025.

  • Quarterly results put Common Equity at $305.8 million for Q4 2025, up 110.22% from a year ago — trailing twelve months through Dec 2025 was $305.8 million (up 110.22% YoY), and the annual figure for FY2025 was $305.8 million, up 110.22%.
  • Common Equity for Q4 2025 was $305.8 million at Capricor Therapeutics, up from $83.9 million in the prior quarter.
  • Over the last five years, Common Equity for CAPR hit a ceiling of $305.8 million in Q4 2025 and a floor of -$1.8 million in Q3 2023.
  • Median Common Equity over the past 5 years was $28.0 million (2021), compared with a mean of $55.2 million.
  • Biggest five-year swings in Common Equity: plummeted 111.59% in 2023 and later skyrocketed 3918.69% in 2024.
  • Capricor Therapeutics' Common Equity stood at $31.4 million in 2021, then tumbled by 62.43% to $11.8 million in 2022, then soared by 91.76% to $22.6 million in 2023, then soared by 543.6% to $145.5 million in 2024, then skyrocketed by 110.22% to $305.8 million in 2025.
  • The last three reported values for Common Equity were $305.8 million (Q4 2025), $83.9 million (Q3 2025), and $105.0 million (Q2 2025) per Business Quant data.